» Articles » PMID: 19192645

Perioperative High-dose Rate Brachytherapy Using a Bendy Applicator (flab): Treatment Results of 74 Patients

Overview
Journal Anticancer Res
Specialty Oncology
Date 2009 Feb 6
PMID 19192645
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Radiotherapy plays a pivotal role in tumor treatment. Brachytherapy as an additional radiation technique allows local dose increments in areas at high risk of local failure.

Patients And Methods: Our past 15-year experience with tissue-equivalent bendy applicator brachytherapy at the University Hospital Münster, Germany was reviewed. A series of 74 consecutive patients who had mainly been treated for sarcomas with perioperative brachytherapy was analyzed with a focus on local relapse-free survival and side-effects.

Results: The 5-year local control rate was 73% in primary treatment situations with a significant influence of additional external irradiation, surgical margin depth and tumor entity. Late sequelae of combined modality treatment were observed in 40 patients (54%) and mainly concerned wound healing (n = 18, 24%).

Conclusion: A high-risk collective, in view of local failure, showed adequate local control rates as well as acceptable late sequelae. Flab brachytherapy is a good treatment option to achieve local radiation dose increments in patients at high risk of local failure.

Citing Articles

MicroRNA-504 modulates osteosarcoma cell chemoresistance to cisplatin by targeting p53.

Chen X, Lv C, Zhu X, Lin W, Wang L, Huang Z Oncol Lett. 2019; 17(2):1664-1674.

PMID: 30675226 PMC: 6341607. DOI: 10.3892/ol.2018.9749.


Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation.

Deng Z, Liu X, Jin J, Xu H, Gao Q, Wang Y Int J Biol Sci. 2016; 12(11):1298-1308.

PMID: 27877082 PMC: 5118776. DOI: 10.7150/ijbs.16569.


Transcription factor NF‑YA promotes a malignant phenotype by upregulating fatty acid synthase expression.

Guo J, Kong L, Peng A, Long X, Zhou Y, Shu Y Mol Med Rep. 2016; 14(6):5007-5014.

PMID: 27840951 PMC: 5355697. DOI: 10.3892/mmr.2016.5897.


microRNA-363 plays a tumor suppressive role in osteosarcoma by directly targeting MAP2K4.

Li X, Liu X, Fang J, Li H, Chen J Int J Clin Exp Med. 2016; 8(11):20157-67.

PMID: 26884928 PMC: 4723773.


microRNA-195 suppresses osteosarcoma cell invasion and migration in vitro by targeting FASN.

Hua Mao J, Zhou R, Peng A, Liu Z, Huang S, Long X Oncol Lett. 2012; 4(5):1125-1129.

PMID: 23162665 PMC: 3499598. DOI: 10.3892/ol.2012.863.